AveXis (AVXS) Reports Plan to Commence Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
Tweet Send to a Friend
AveXis, Inc. (NASDAQ: AVXS) today announced the U.S. Food and Drug Administration (FDA) has notified the company that, based on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
